

Figure S3. GL21.T-miR-16 conjugate. (**a**), Secondary structure predicted by using RNAstructure *v4.5.* of GL21.T-miR-16. (**b**) GL21.T-miR-16 Dicer processing *in vitro*. The indicated RNAs were untreated or treated with recombinant Dicer, resolved on a nondenaturing polyacrylamide gel and stained with ethidium bromide. (**c**) Meg-01 cells (Axl and miR-16 negative), were transfected with Axl TruClone (Meg-01-Axl). Following 24 h cells were transfected (Transf.) with miR-16 or ctrl-miR or were treated (Treat.) with 400nM of GL21.T-miR-16 or GL21.T. Following 48 h, cell extracts were immunoblotted with anti-Bcl-2 (validated target of miR-16) and anti-αtubulin antibodies (*left)*, miR-16 levels were quantified by RT-qPCR (*right*). Intensity of bands was calculated using NIH ImageJ and expressed relative to mock-treated cells, arbitrarily set to 1 ("-", labeled with asterisk). Error bars depict means ± S.D. (N = 3).